流感季来袭，华兰生物加大疫苗供应

Core Viewpoint - The peak of influenza cases in China is expected to occur in mid to late December this year and early January next year, with the H3N2 subtype dominating the current flu activity [2]. Group 1: Industry Overview - The overall influenza activity in China is currently on the rise, with the H3N2 subtype accounting for over 95% of cases, alongside a small presence of H1N1 and B-type influenza viruses [2]. - The China Disease Control and Prevention Center has indicated a significant increase in public awareness regarding flu vaccinations since October, particularly in November, leading to a notable rise in demand orders from local disease control centers compared to the same period last year [2]. Group 2: Company Insights - Hualan Biological Engineering, through its subsidiary Hualan Vaccine Co., is the largest producer of influenza vaccines in China, with an annual production capacity of 100 million doses [2]. - The company has maintained a leading position in both production and sales of influenza vaccines since the introduction of the first quadrivalent influenza vaccine in 2018, emphasizing high-quality products [2]. - Hualan Biological has committed to high standards of vaccine quality control and stability monitoring, ensuring the provision of high-quality and competitively priced vaccine products [3].